{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:51:26Z","timestamp":1761897086912},"reference-count":0,"publisher":"BioExcel","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"DOI":"10.7573\/dic.212603","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T05:41:42Z","timestamp":1569476502000},"page":"1-16","source":"Crossref","is-referenced-by-count":5,"title":["Standard care and investigational drugs in the treatment of myelofibrosis"],"prefix":"10.7573","volume":"8","author":[{"given":"Daniela","family":"Barraco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10047","published-online":{"date-parts":[[2019,9,26]]},"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2019\/09\/dic.212603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T15:02:38Z","timestamp":1578668558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/standard-care-and-investigational-drugs-in-the-treatment-of-myelofibrosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":0,"URL":"https:\/\/doi.org\/10.7573\/dic.212603","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]}}}